Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK: How our brains fend off madness, we produce a cannabis-like substance

Medical News today

Thursday 26 Aug 2004

---

A cannabis like substance produced by the brain may dampen delusional or
psychotic experiences, rather than trigger them.

Heavy cannabis use has been linked to psychosis in the past, leading
researchers to look for a connection between the brain's natural cannabinoid
system and schizophrenia. Sure enough, when Markus Leweke of the University of
Cologne, Germany, and Andrea Giuffrida and Danielle Piomelli of the University
of California, Irvine, looked at levels of the natural cannabis-like substance
anandamide, they were higher in people with schizophrenia than in healthy
controls.

The team measured levels of anandamide in the cerebrospinal fluid (CSF) of 47
people suffering their first bout of schizophrenia, but who had not yet taken
any drugs for it, and 26 people who had symptoms of psychosis and have a high
risk of schizophrenia. Compared with 84 healthy volunteers, levels were six
times as high in people with symptoms of psychosis and eight times as high in
those with schizophrenia.

"This is a massive increase in anandamide levels," Leweke told the National
Cannabis and Mental Illness Conference in Melbourne, Australia, last week. And
that is just in the CSF. Levels could be a hundred times higher in the
synapses, where nerve signalling is taking place, he says.

But were the high anandamide levels triggering the psychotic symptoms or a
response to them? Leweke and his colleagues found, to their surprise, that the
more severe people's schizophrenia was the lower their anandamide levels. The
team's theory is that rather than triggering psychosis, the substance is
released in response to psychotic symptoms to help control them. People with
the worst symptoms might be unable to produce sufficient anandamide to prevent
them.

At some point in their lives, between 5 and 30 per cent of healthy people have
had symptoms such as delusions or hallucinations, which can be triggered by
something as simple as sleep deprivation. "All of us are potentially
psychotic," says David Castle of the University of Melbourne.

So for the body to have a system that prevents these experiences getting out of
hand makes sense, he says. The new findings suggest antipsychotic drugs could
be developed that target the anandamide system, but it will not be simple. The
active ingredient in cannabis, THC, binds to anandamide receptors. But people
with schizophrenia who use cannabis actually have more severe and frequent
psychotic episodes than those who do not.

This may be because THC makes anandamide receptors less sensitive. Leweke's
team also found anandamide levels lowest in people with schizophrenia who used
cannabis more frequently, suggesting it may disrupt the system in other ways
too.

Up to 60 per cent of people with schizophrenia use cannabis. A study by Castle,
also reported at the Melbourne meeting, has found that people use the drug to
get rid of unpleasant emotions associated with the disease such as anxiety and
depression. This article appears in New Scientist issue: 28 August 2004

PLEASE MENTION NEW SCIENTIST AS THE SOURCE OF THIS STORY AND, IF PUBLISHING
ONLINE, PLEASE CARRY A HYPERLINK TO: http://www.newscientist.com

"These articles are posted on this site to give advance access to other
authorised media who may wish to quote extracts as part of fair dealing with
this copyrighted material. Full attribution is required, and if publishing
online a link to www.newscientist.com is also required. Advance permission is
required before any and every reproduction of each article in full - please
contact celia.thomas@rbi.co.uk. Please note that all material is copyright of
Reed Business Information Limited and we reserve the right to take such action
as we consider appropriate to protect such copyright."

UK CONTACT: Claire Bowles
claire.bowles@rbi.co.uk
44-20-7331-2751
New Scientist Press Office, London
US CONTACT: Toni Marshall
toni.marshall@newscientist.com
1-617-558-4939
New Scientist Boston office

 

 

 

After you have finished reading this article you can click here to go back.




This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!